Seattle Genetics, Inc. and Millennium The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top-line results from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 58 relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) patients.

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.

As a part of a $30 million dollar National Institutes of Health (NIH) initiative to map the human brain, Saint Louis University neurosurgeon Richard Bucholz, M.D. will image the brains of healthy adults with MEG technology, providing key information about brain function.

Earlier belief that happiness is a genetic trait influenced by early life experiences has been contradicted by new research from Germany. This new study found that feelings of happiness and wellbeing respond to external factors such as healthy lifestyle, religion and working hours. The study was published in the Proceedings of the National Academy of Sciences.

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.